$ACON Cashflow Statement | Understand Stock

$ACON

$1.92 -$0.01 (0.52%) Close

$ACON Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Share-based compensation
Amendment of warrants
Non-cash settlements
Loss on exchange of debt
Loss on extinguishment of debt
Amortization of deferred issuance costs
Change in fair value related to warrants and derivative
Non-cash interest related to bridge funding
Gain on forgiveness of PPP loans
Share-based vendor payments
Loss on disposal of furniture and equipment
Changes in fair value of redeemable preferred stock
Interest conversion discount settled in equity
Warrants issued as non- cash finance charge
Non-cash expenses related to equity line agreement

Change in operating assets and liabilities
Accounts receivable
Prepaids and other current assets
Accounts payable
Accrued and other liabilities
Accrued interest on promissory and convertible notes
Net cash used in operating activities
Proceeds from sale of furniture
Intangible assets – Patents
Fixed assets
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of PPP Loan
Proceeds from issuance of convertible notes
Bridge funding cash issuance costs
Equity line issuance costs
Public offering of common stock and warrants
Registered direct offerings of common stock
Proceeds from direct offering of prefunded warrants
Proceeds from sale of preferred stock
Redemption of preferred stock
Proceeds from sale of common stock and warrants, Reg A+
Proceeds from sale of common stock and warrants, ATM
Common stock cash issuance costs
Exercise of Series C warrants
Redemption of Series B Preferred stock
Proceeds from common stock and warrant RegA+ offering
Proceeds from equity line
Proceeds from issuance of promissory notes
Repayment of promissory notes
Issuance of common stock and warrants related to IPO, net issuance costs
Proceeds from sale of common stock and warrants related to public offering
Equity line cash issuance costs
Preferred stock cash issuance costs
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period

Supplemental disclosures
Cash paid for interest
Cash paid for income taxes
Non-cash activities
Conversion of indebtedness to preferred equity commitment
Accrued debt issuance costs related to bridge funding
Accrued debt issuance costs related to equity line
Issuance of warrants related to bridge funding
Original issuance discount (15%) related to bridge funding
Liability to issue common shares
Capitalization of Series B preferred stock dividends
Capitalization of Series C preferred stock dividends
Conversion of Series C preferred stock to common stock
Cashless exercise of B warrants to common stock
Dividends accrued on preferred shares
Exchange of indebtedness for common shares
Exchange of indebtedness for preferred shares
Conversion of preferred stock to common stock
Conversion of preferred stock dividends to common stock
Conversion of accrued interest on promissory notes to common stock and warrants
Issuance of underwriter's warrants related to IPO
Changes in fair value of redeemable preferred stock
Designation of prepaid expenses to IPO issuance costs
Issuance of common shares related to restricted stock units
Issuance of commitment shares related to bridge funding
Fair value of warrants and derivative related to first tranche bridge funding
Fair value of warrants and derivative related to second tranche bridge funding
Fair value of warrants and derivative related to third tranche bridge funding

Comments